The adage “all things in moderation” applies not to just to food and drink, but also to the legions of bacteria inside our guts helping us digest that food and drink. It turns out the […]
ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug […]
Pendulum Therapeutics, an evidence-based microbiome company, announced today the publication of their clinical study in the journal BMJ Open Diabetes Research & Care showing the effectiveness of Pendulum’s novel medical probiotic, Pendulum Glucose Control. The […]
Biose Industrie announced the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the Auvergne-Rhône-Alpes region. Thanks to this funding found, Biose Industrie will benefit […]
The brain-gut-microbiota axis is viewed as a novel paradigm in neuroscience and it is abundantly evident that the traditional approaches to developing pharmacological strategies for psychiatric illnesses are no longer yielding results. There has been no […]
–Azitra, Inc., a clinical-stage medical dermatology biotech company addressing serious skin conditions by harnessing the microbiome, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,702,558 to the Company […]